A Phase IIIB, Randomized, Trial of Open-label Non- Nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) with another PI in Combination with Double-Blind Comparison of two Nucleoside Reverse Transcriptase Inhibitor (NRTI) or a different NRTI in Antiretroviral-Naїve Subjects

This study is being done to compare the effectiveness, safety, and tolerability of anti-HIV drug combinations. At entry subjects will be randomized to four groups with all study drugs being provided by the study. All of the drugs are approved by the United States Food and Drug Administration (FDA) for treating HIV. Subjects will participate in this study for 96 weeks beyond the enrollment of the last subject.  

• Men and women who are 18 years old or older
• HIV-1 infection
• Screening HIV-1 RNA more than 1000 copies/mL within 90 days prior to study entry
• Antiretroviral drug-naïve, defined as 7 days or less of treatment at any time prior to entry